P43: France adopts a 3D diagnosis strategy for its National Alzheimer databank – An optimization of patient selection for clinical trials
Pierre Krolak-Salmon1, MD, PhD, Philippe Robert2 MD, PhD, Eric Asseman3, MD, Claudine Berr4 8, PhD, Mathieu Cecalddi5, MD, PhD, Bruno Dubois6, MD, PhD, Stephane Eipelbaum6, MD, PhD, Bruno Vellas7, MD, PhD, Audrey Gabelle8, MD, PhD
(1)Clinical and Research Memory Centre of Lyon, Hospices civils de Lyon, University Lyon 1, INSERM U1028, UMR CNRS 5292, Lyon, France (2) Clinical and Research Memory Centre of Nice, France (3)Memory Clinic Alpes Nord, France (4)Inserm U1061, University of Montpellier, 34093 Montpellier, France (5)Clinical and Research Memory Centre of Marseille, France (6)Clinical and Research Memory Centre of Paris Pitié-Salpêtrière, France (7)Clinical and Research Memory Centre of Toulouse, France (8)Clinical and Research Memory Centre of Montpellier, France

P44: Divergent topological networks of grey and white matter in Alzheimer’s disease: A diffusion kurtosis imaging analysis
Jun Xu 1, Hongying Zhang2, Jiaxing Cheng1
(1)Neurology Department, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou, China (2) Radiology Department, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou, China

P45 Impact of two distinct MRI parallel imaging implementations on hippocampal volume estimates obtained from two methodologically different methods
Oliver Peters, MD1, Per Suppa2 3, Catharina Lange, MSc3, Ralph Buchert, PhD4, Lothar Spies, PhD2, Isabella Heuser, MD, PhD1
(1) Department of Psychiatry, Charité, Berlin, Germany (2) jung diagnostics GmbH, Hamburg, Germany (3) Department of Nuclear Medicine, Charité, Berlin, Germany (4) Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Germany

P46 MRI markers of neurodegeneration in preclinical Alzheimer’s disease
Adam J. Schwarz, PhD1, Michael G. Case, MS1, Peter F. Castelluccio, MS1, AnnCatherine M. Downing, PharmD1, John R. Sims, MD1, James B. Brewer, MD, PhD2, Anja Soldan, PhD3, Corrine A. Pettigrew, PhD1, Marilyn Albert, PhD3
(1) Eli Lilly and Company, Indianapolis, IN, USA (2) University of California, San Diego, CA, USA (3) Johns Hopkins University, Baltimore, MD, USA

P47: FDA Qualification of Intracranial Adjusted Hippocampal Volumetric Magnetic Resonance Imaging (ICV-HV vMRI) as a Prognostic Biomarker for Pre-Dementia Clinical Trials for Alzheimer disease Therapeutics
Daniela J. Conrado, PhD1, Klaus Romero, MS, MD1, Derek L. Hill, PhD2, Patricia Cole, MD, PhD3, Dawn Matthews, PhD4, Gerald Novak, MD5, Volker D. Kern, PhD1, Robin Wolz, PhD2, Richard Meibach, PhD5, Jackson Burton, PhD1, Brian Corrigan, PhD3, Timothy Nicholas, PhD7, Danny Chen, PhD7, Julie Stone, PhD8, Vikram Sinha, PhD9, Brian Willis, PhD9, Wenping Wang, PhD9, Stephen P. Arneric, PhD1
(1) Critical Path Institute, Tucson, AZ, USA (2) IXICO, London, United Kingdom (3) Advisor, MA, USA (4) ADMDX, Chicago, IL, USA (5) Janssen Pharmaceuticals (J&J), Titusville, NJ, USA (6) Advisor, NJ, USA (7) Pfizer Inc, Groton, CT, USA (8) Merck, West Point, PA, USA (9) Eli Lilly, Indianapolis, IN, USA

P48: Cerebral Atrophy in Alzheimer’s Disease Patients: Effect of Combined Therapy Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor, Choline Alphoscerate
Enea Traini, PhD1, Anna Carotenuto, PhD1 2, Angiola Maria Fasanaro, MD2, Francesco Amenta, MD1
(1) Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino, Italy
P49: Cerebral hypoperfusion is not associated with an increase in β-amyloid pathology.
Ruben Smith, MD, PhD1,2, Sebastian Palmqvist, MD, PhD1,2, Hanna Ljung, MS2,3, Tobias Cronberg, MD, PhD2,3, Danielle van Westen, MD, PhD1 and Oskar Hansson, MD, PhD1,5
(1) Lund University, Clinical Memory Research Unit, Dept. of Clinical Sciences Malmö, Malmö, Sweden. (2) Skåne University Hospital, Dept. of Neurology, Lund, Sweden. (3) Lund University, Skane University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden (4) Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Diagnostic radiology, Lund, Sweden. (5) Skåne University Hospital, Memory clinic, Malmö, Sweden.

P50: Optimized detection of disease and treatment effect in preclinical and prodromal autosomal dominant Alzheimer’s disease with imaging biomarkers
Dawn C Matthews MS MM1, Ana S Lukic PhD1, Randolph D Andrews MS1, Miles N Wernick PhD1,2, Stephen C Strother PhD1,5, Tammie L S Benzinger MD PhD4,5, Dominantly Inherited Alzheimer Network

P51: Cognitive Function and Prevalence of Amyloid Pathology in Frail Adults – The COGFRAIL Study
Sourdet S, MD1, Soriano G, RD1, Steinmeyer Z, MD1, Delrieu J, MD1, Ousset PJ, MD1, Vellas B, MD, PhD2.
(1)Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

P52: Hippocampal volume is weakly associated with amyloid beta levels in asymptomatic individuals at risk for Alzheimer’s disease: findings from the CHARIOT-PRO Sub-Study
Derrek P. Hibar1, Ziad Saad1, Hartmuth Kolb1, Gerald Novak2, Nzeera Ketter2, Nandini Raghavan2, Chi Udeh-Momoh3, Tina Mansoor1, Michael Ropacki4, Sherry Meeh2, Robert Perneckzy3, Steve Einstein2, Gary Roman2 and Lefkos Middleton3
(1)Janssen Neuroscience LLC, California, USA (2)Janssen Neuroscience LLC, New Jersey, USA (3)Neuroepidemiology and Ageing Research, Imperial College London, London, UK (4)MedAvante Inc., New Jersey, USA

P53: Impact on Sample Size and Screening Using Amyloid Visual Read versus Quantitative Values for Inclusion
Donald G. McLaren, PhD1, Felix Carbonell, PhD1, Alex P. Zijdenbos, PhD1, Barry J. Bedell, MD,PhD1,2
(1) Biospective Inc., Montreal, Quebec, Canada (2)McGill University, Montreal, Quebec, Canada

P54: Automated voxel-based Tau PET quantitation in early Alzheimer's Disease: Association of hippocampus masked SUVR with baseline cognition
Arthur Mikhno, PhD1, Janos Redei, MD, PhD1, J John Mann, MD2,3, Ramin Parsey, MD, PhD4
(1) i2Dx, Inc., San Francisco, CA, USA (2) Columbia University, New York, NY, USA (3) New York State Psychiatric Institute, New York, NY, USA (4) Stony Brook University, Stony Brook, NY, USA

P55: Inter and Intra PET Scanner Variability in Multi-Center Clinical Trials Using the Hoffman Phantom
Katarzyna Adamczuk, PhD1, Beth Gorman, BS CNMT2, Maureen Runkle, BS CNMT2, Nicolas Pannetier, PhD1, David Scott, PhD1, Joyce Suhuy, PhD1
(1)Bioclinica, Newark, CA, USA; 2Bioclinica, Philadelphia, PA, USA